CSL Seqirus partnership expanded; UK to introduce AUJEMFLU (aTIVc)
CSL Seqirus says it has strengthened its partnership with the UK Government, with the UK set to be the first country to introduce AUJEMFLU (adjuvanted cell-based) flu vaccine (aTIVc) and an extended health security pandemic agreement.
Story updates
11:01:31 PM UTC
SquawkNews
CSL Seqirus will supply its adjuvanted cell-based flu vaccine (aTIVc) to the UK from 2027/28 and has extended a UK influenza pandemic Advance Purchase Agreement enabling optional access to 100M+ doses, with final production at its Liverpool site.Material DetailsContext by AI AnalystThis is a mid-cy…
MAIDENHEAD, England, Sept. 22, 2026 // -- CSL Seqirus, a business of CSL (ASX:CSL; USOTC: CSLLY), today announced a strengthened partnership with the UK Government that will see the UK become the first country in the world to introduce AUJEMFLU (aTIVc), CSL Seqirus' adjuvanted cell-based…